SCHEMBL27162302

SCHEMBL27162302

N#Cc1ccc(CN2CCC3(CC2)CCN(S(=O)(=O)c2ccc(N4CCOC4=O)nc2)C3)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CACNA1H O95180 3/20 0.39
▸ USP2 O75604 3/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ SCN9A Q15858 1/20 0.38
▸ CYP2D6 P10635 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ EGLN2 Q96KS0 1/20 0.37
▸ PARG Q86W56 2/20 0.37
▸ KCNJ1 P48048 1/20 0.37
▸ TRPV4 Q9HBA0 5/20 0.37
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049557 1.00 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNACACNA1HUSP2
SCHEMBL30049837 0.94 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNACACNA1HUSP2
SCHEMBL27162506 0.94 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNACACNA1HUSP2
SCHEMBL30050906 0.92 CYP3A4 (0.47) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL27161913 0.92 CYP3A4 (0.47) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL27162660 0.90 CYP3A4 (0.43) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL30049800 0.90 CYP3A4 (0.43) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL30051119 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL27162256 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4
SCHEMBL30049716 0.86 CYP3A4 (0.47) ALDH1A1SMN1; SMN2LMNAUSP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885SMN1; SMN2 3118/4885LMNA 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback